Read by QxMD icon Read

lung cancer, non small cell lung cancer, prognostic markers

Qian Wang, Shi-Bing Li, Yi-Ying Zhao, Da-Nian Dai, Hui Du, Yan-Zhu Lin, Jia-Cong Ye, Jing Zhao, Wei Xiao, Yan Mei, Yi-Tai Xiao, Shi-Chu Liu, Yan Li, Yun-Fei Xia, Er-Wei Song, Gang-Hua Tang, Wei-Guang Zhang, Zhi-Jiang Li, Xiao-Bin Zheng, De-Hai Cao, Man-Zhi Li, Qian Zhong, Zhong-Ping Chen, Chao-Nan Qian, Wei Fan, Guo-Kai Feng, Mu-Sheng Zeng
The sodium pump Na+ /K+ ATPase a1 subunit(NKA a1), an attractive cancer-related biomarker and therapeutic target, is closely related to the development and progression of several cancers including breast cancer. Currently, a NKA a1 inhibitor, UNBS1450, has already evidenced its great therapeutic potential in personalized cancer treatment. The ability of non-invasive imaging of NKA a1 expression would be useful for selecting cancer patients who may benefit from this drug. Here, we identified an S3 peptide that is specifically homed to breast cancer by phage display...
May 16, 2018: Journal of Controlled Release: Official Journal of the Controlled Release Society
Yusuke Nakamura, Masaya Mukai, Shinichiro Hiraiwa, Kyoko Kishima, Tomoko Sugiyama, Takuma Tajiri, Shunsuke Yamada, Masayuki Iwazaki
Previous studies demonstrated that free‑floating cancer cells (FFCCs) in the lymph node sinuses were of prognostic significance for colorectal and gastric cancer. The present study investigated the clinical significance of detecting FFCCs using Fast Red staining for cytokeratin in stage I/II non‑small cell lung cancer (NSCLC) patients and hilar lymph node positive NSCLC patients who underwent curative resection. Between 2002 and 2011, a total of 164 patients (including 22 hilar lymph node positive patients) were investigated...
May 14, 2018: Molecular Medicine Reports
Yu-Chun Chang, Yan Ding, Lingsheng Dong, Lang-Jing Zhu, Roderick V Jensen, Li-Li Hsiao
Background: Using DNA microarrays, we previously identified 451 genes expressed in 19 different human tissues. Although ubiquitously expressed, the variable expression patterns of these "housekeeping genes" (HKGs) could separate one normal human tissue type from another. Current focus on identifying "specific disease markers" is problematic as single gene expression in a given sample represents the specific cellular states of the sample at the time of collection. In this study, we examine the diagnostic and prognostic potential of the variable expressions of HKGs in lung cancers...
2018: PeerJ
Dan Wang, Gui-Min Wen, Wei Hou, Pu Xia
BACKGROUND: This study was carried out to investigate the correlation between CD133 and non-small cell lung cancer (NSCLC) clinicopathological features and its impact on survival of the patients with NSCLC. METHODS: In the first, we detected the level and localization of CD133 protein in NSCLC specimens and confirmed that CD133 expression was closely linked to poor prognosis of NSCLC. Secondly, TCGA genomic data for LUNG (Provisional) was retrieved and analyzed for genetic alterations of CD133 in different lung cancer subtypes...
May 4, 2018: Cancer Biomarkers: Section A of Disease Markers
Jingmei Ye, Jiani Wang, Nana Zhang, Yu Liu, Li Tan, Lihua Xu
The aim of the present study was to investigate the expression of transactivation response RNA-binding protein (TARBP)1 and its clinical significance in human non-small-cell lung cancer (NSCLC). TARBP1 expression at the mRNA level was detected by reverse transcription-quantitative polymerase chain reaction (RT-qPCR) in 10 NSCLC tissues and paired adjacent normal tissues. TARBP1 protein expression was analyzed in 90 paraffin-embedded NSCLC tissue samples and paired adjacent normal tissues by immunohistochemistry...
May 2018: Oncology Letters
Changjiang Feng, Jiaqi Wu, Fan Yang, Mangtang Qiu, Shuofeng Hu, Saisai Guo, Jin Wu, Xiaomin Ying, Jun Wang
Lung squamous cell carcinoma (LUSC) is the second major type of lung cancer globally. The majority of patients with LUSC are clinically diagnosed at the advanced stages, thus it is urgent to identify suitable prognostic markers for LUSC. B-cell lymphoma 2 (Bcl-2) has been widely studied in non-small cell lung cancer (NSCLC). However, the prognostic role of Bcl-2 in NSCLC remains conflicting and controversial, particularly for LUSC. Although certain studies have been performed to identify the prognostic value of Bcl-2, to the best of our knowledge, no study has investigated the prognostic role of Bcl-2 in LUSC specifically...
May 2018: Oncology Letters
Jiguang Jia, Bin Huang, Zhengling Zhuang, Sen Chen
PURPOSE: Bone metastases from non-small cell lung cancer (NSCLC) are common, and current prognostic stratification methods are challenging to predict outcomes. The aim of the study is to examine circulating tumor DNA as a potential biomarker to gauge overall survival. METHODS: Late stage NSCLC patients associated with bone metastasis were recruited for the study. Circulating tumor DNA was quantified using droplet digital polymerase chain reaction, a sensitive assay that is capable to pick up low mutant DNA frequencies...
April 1, 2018: International Journal of Biological Markers
Junghoon Shin, Kyu Sang Lee, Kyung Ah Yoh, Hyun Jin Cho, Moon Ki Choi, Se Hyun Kim, Yu Jung Kim, Jin-Haeng Chung, Sukki Cho, Kwhanmien Kim, Sanghoon Jheon, Ho Il Yoon, Jae Ho Lee, Choon-Taek Lee, Jong Seok Lee
OBJECTIVE: Multimodal treatments that include preoperative platinum-based chemotherapy are fundamental to the treatment of advanced non-small cell lung cancer (NSCLC). This study aimed to investigate the predictive value of DNA repair protein expression in surgically resected NSCLCs in terms of prognosis and responses to platinum-containing chemotherapy. METHODS: This retrospective study included 136 patients with NSCLC who were treated with preoperative platinum-based chemotherapy, followed by curative lung resection...
April 25, 2018: Oncology
Annalisa Milano, Francesca Mazzetta, Sabatino Valente, Danilo Ranieri, Laura Leone, Andrea Botticelli, Concetta Elisa Onesti, Salvatore Lauro, Salvatore Raffa, Maria Rosaria Torrisi, Paolo Marchetti
Background: Non-small cell lung cancer (NSCLC) is the most common cause of cancer-related mortality; nevertheless, there are few data regarding detection of circulating tumor cells (CTCs) in NSCLC, compared to other kinds of cancers in which their prognostic roles have already been defined. This difference is likely due to detection methods based on the epithelial marker expression which ignore CTCs undergoing epithelial-mesenchymal transition (CTCsEMT ). Methods: After optimization of the test with spiking experiments of A549 cells undergoing TGF- β 1-induced EMT (A549EMT ), the CTCsEMT were enriched by immunomagnetic depletion of leukocytes and then characterized by a RT-PCR assay based on the retrieval of epithelial and EMT-related genes...
2018: Analytical Cellular Pathology (Amsterdam)
William Sterlacci, Michael Fiegl, Lothar Veits, Alexandar Tzankov
Background: The prognostic significance and clinico-pathological characterization of mucin (MUC) expression in non-small cell lung cancer (NSCLC) is controversial and little studied. Aims: This study aims at elucidating this issue on the largest and most detailed cohort so far. Settings and Design: We examined the expression of MUC 1, 2, 4, 5AC and 6 on 371, well documented, surgically resected NSCLC cases. Materials and Methods: Immunohistochemical results were correlated with several of our previously studied, relevant parameters on this cohort including a follow-up period of up to 20 years...
April 2018: Indian Journal of Pathology & Microbiology
Efimia Boutsikou, Kalliopi Domvri, Georgia Hardavella, Dora Tsiouda, Konstantinos Zarogoulidis, Theodoros Kontakiotis
Background: The emergence of novel antiprogrammed cell death protein-1 (PD-1) inhibitors in non-small cell lung cancers (NSCLC) has revolutionized the therapeutic landscape of this disease. Although overall survival (OS) has improved in the first- and second-line therapy settings for advanced NSCLC, the benefit is not universal. In a climate of global scrutiny for healthcare costs and potential for toxicities related to immunotherapy, appropriate patient selection is crucial. The aim of this study was to evaluate potential prognostic and predictive biomarkers interferon-gamma (IFN-γ), tumour necrosis factor-alpha (TNF-α) and a panel of interleukins (ILs) in the peripheral blood, and assess any correlation with response to anti-PD-1 inhibition, progression-free survival and OS in NSCLC patients...
2018: Therapeutic Advances in Medical Oncology
Yeon-Koo Kang, Yoo Sung Song, Sukki Cho, Sanghoon Jheon, Won Woo Lee, Kwhanmien Kim, Sang Eun Kim
PURPOSE: In the management of non-small cell lung cancer (NSCLC), the prognostic stratification of stage I tumors without indication of adjuvant therapy, remains to be elucidated in order to better select patients who can benefit from additional therapies. We aimed to stratify the prognosis of patients with stage I NSCLC adenocarcinoma using clinicopathologic factors and F-18 FDG PET. MATERIALS AND METHODS: We retrospectively enrolled 128 patients with stage I NSCLC without any high-risk factors, who underwent curative surgical resection without adjuvant therapies...
May 2018: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
Sipeng Shen, Ruyang Zhang, Yichen Guo, Elizabeth Loehrer, Yongyue Wei, Ying Zhu, Qianyu Yuan, Sebastian Moran, Thomas Fleischer, Maria M Bjaanaes, Anna Karlsson, Maria Planck, Johan Staaf, Åslaug Helland, Manel Esteller, Li Su, Feng Chen, David C Christiani
B-cell translocation gene 2 (BTG2) is a tumour suppressor protein known to be downregulated in several types of cancer. In this study, we investigated a potential role for BTG2 in early-stage non-small cell lung cancer (NSCLC) survival. We analysed BTG2 methylation data from 1230 early-stage NSCLC patients from five international cohorts, as well as gene expression data from 3038 lung cancer cases from multiple cohorts. Three CpG probes (cg01798157, cg06373167, cg23371584) that detected BTG2 hypermethylation in tumour tissues were associated with lower overall survival...
April 15, 2018: Molecular Oncology
Rui Xu, Sheng-Yu Wang, Li Wang, Man-Xiang Li, Yang Yao
OBJECTIVE: To investigate the expression of CHCHD2, a potential tumor marker, in tumor and adjacent tissues from patients with non-small cell lung cancer (NSCLC). METHODS: Immunohistochemistry was used to detect the expression and location of CHCHD2 in the tumor tissues from 60 patients with NSCLC and 35 adjacent tissues to analyze the correlation of CHCHD2 expression with the clinicopathological variables and overall survival of the patients. The expression profile of CHCHD2 mRNA in NSCLC was analyzed using Oncomine database...
March 20, 2018: Nan Fang Yi Ke da Xue Xue Bao, Journal of Southern Medical University
Angelo Castello, Fabio Grizzi, Luca Toschi, Sabrina Rossi, Daoud Rahal, Federica Marchesi, Carlo Russo, Giovanna Finocchiaro, Egesta Lopci
OBJECTIVES: This study aimed to determine the prognostic role of textural features and their association with metabolic parameters, hypoxia, and cancer-related immune markers in non-small-cell lung cancer (NSCLC) patients. PATIENTS AND METHODS: The trial was registered at (NCT02519062). From January 2010 to May 2014, 44 patients (male : female=33 : 11; median age: 69.5 years), referred to our Institution for NSCLC resection, were enrolled...
March 30, 2018: Nuclear Medicine Communications
Seigo Minami, Shouichi Ihara, Sung-Ho Kim, Suguru Yamamoto, Kiyoshi Komuta
Background: Neutrophil to lymphocyte ratio (NLR), lymphocyte to monocyte ratio (LMR) and modified Glasgow prognostic score (mGPS) are useful prognostic markers based on host-related systemic inflammatory response. They have been shown as independent prognostic biomarkers in various cancers, including non-small cell lung cancer. However, there has been little evidence for a specific population of pulmonary adenocarcinoma without active epidermal growth factor receptor (EGFR) mutation. Methods: We retrospectively reviewed 159 patients who met the following criteria: histologically or cytologically diagnosed adenocarcinoma, confirmed wild-type EGFR, started first-line cytotoxic chemotherapy between July 2007 and March 2017 at our hospital, and c-stage IIIB or IV...
February 2018: World Journal of Oncology
Uri Barash, Moshe Lapidot, Yaniv Zohar, Cynthia Loomis, Andre Moreira, Sari Feld, Chandra Goparaju, Haining Yang, Edward Hammond, Ganlin Zhang, Jin-Ping Li, Neta Ilan, Arnon Nagler, Harvey I Pass, Israel Vlodavsky
Background: Mammalian cells express a single functional heparanase, an endoglycosidase that cleaves heparan sulfate and thereby promotes tumor metastasis, angiogenesis, and inflammation. Malignant mesothelioma is highly aggressive and has a poor prognosis because of the lack of markers for early diagnosis and resistance to conventional therapies. The purpose of this study was to elucidate the mode of action and biological significance of heparanase in mesothelioma and test the efficacy of heparanase inhibitors in the treatment of this malignancy...
March 21, 2018: Journal of the National Cancer Institute
Chun Hua Xu, Chuan Zhen Chi, Qian Zhang, Yu Chao Wang, Wei Wang, Qi Yuan, Ping Zhan, Xiu Wei Zhang, Yong Lin
INTRODUCTION: Cripto-1 (CR-1) is a member of the epidermal growth factor (EGF)-CFC protein family, which is involved in tumor pathogenesis. OBJECTIVES: This study aimed to explore the diagnostic and prognostic value of serum CR-1 level in patients with non-small cell lung cancer (NSCLC). METHOD: Serum specimens from 312 NSCLC patients and 120 healthy controls were collected. Serum CR-1 level was measured using enzyme-linked immunosorbent assay (ELISA)...
March 23, 2018: Clinical Respiratory Journal
Yury Kiselev, Sigve Andersen, Charles Johannessen, Bjørn Fjukstad, Karina Standahl Olsen, Helge Stenvold, Samer Al-Saad, Tom Donnem, Elin Richardsen, Roy M Bremnes, Lill-Tove Rasmussen Busund
Lung cancer is the leading cause of cancer deaths. Novel predictive biomarkers are needed to improve treatment selection and more accurate prognostication. PAX6 is a transcription factor with a proposed tumour suppressor function. Immunohistochemical staining was performed on tissue microarrays from 335 non-small cell lung cancer (NSCLC) patients for PAX6. Multivariate analyses of clinico-pathological variables and disease-specific survival (DSS) was carried out, and phenotypic changes of two NSCLC cell lines with knockdown of PAX6 were characterized...
March 22, 2018: Scientific Reports
Wuhao Huang, Shengguang Wang, Hua Zhang, Bin Zhang, Changli Wang
Objective: Cancer-associated inflammation and coagulation cascades play vital roles in cancer progression and survival. In this study, we investigated the significance of the combination of preoperative fibrinogen and the neutrophil-to-lymphocyte ratio (NLR) in predicting the survival of patients with non-small cell lung cancer (NSCLC). Methods: We retrospectively enrolled 589 patients with NSCLC who underwent surgery. The univariate and multivariate Cox survival analyses were used to evaluate the prognostic indicators, including the combination of fibrinogen and NLR (F-NLR)...
February 2018: Cancer Biology & Medicine
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"